Current SATVI news
SATVI Director Professor Mark Hatherill has co-authored a commentary titled "WHO preferred product characteristics for new vaccines against tuberculosis" appearing in The Lancet journal.
Associate Professor Tom Scriba has co authored a paper titled "Can we predict tuberculosis cure? What tools are available?" appearing in the European Respiratory Journal of the European Respiratory Society.
Watch the press conference during which the primary results from the M72/AS01E candidate vaccine were announced during the Union World Conference on Lung Health. Professor Mark Hatherill, SATVI Director spoke on behalf of SATVI.
View the full list of SATVI speakers at the The Union World Conference on Lung Health held from 24 to 27 October 2018.
The New England Journal of Medicine has just published the primary results of an ongoing phase IIb clinical trial testing the candidate tuberculosis vaccine M72/AS01E which demonstrates that the M72/AS01E vaccine significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults who were already infected with latent TB at the time of vaccination.
SATVI Researcher Marwou de Kock has co-authored a research article titled: "PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells Is Associated With Bacterial Load in Human Tuberculosis" appearing in the Frontiers in Immunology journal.
SATVI Associate Professor Tom Scriba has co-authored a research paper titled "Differential DNA methylation of potassium channel KCa3.1 and immune signalling pathways is associated with infant immune responses following BCG vaccination" appearing in the Scientific Reports journal.
SATVI and the Western Department of Education are pleased to announce the hosting of the Kick TB Poster Art and Writing Exhibit on Monday 3 September 2018.
SATVI authors Associate Professor Tom Scriba, Drs. Elisa Nemes, Adam Penn-Nicholson, Virginie Rozot and Fatoumatta Darboe have co-authored an article titled: "A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes" appearing in the Nature Journal.
Associate Professor Tom Scriba has co-authored a research paper titled: "Integrating Non-human Primate, Human, and Mathematical Studies to Determine the Influence of BCG Timing on H56 Vaccine Outcomes" appearing in the Frontiers journal.
SATVI Authors dr Elisa Nemes, Professor Mark Hatherill and Associate Professor Tom Scriba have published a paper titled: "Prospects for a vaccine to prevent HIV related Tuberculosis" appearing in the Current opinions in HIV/AIDS journal.